Breaking News Instant updates and real-time market news.

TWTR

Twitter

$24.87

1.35 (5.74%)

, GOOG

Alphabet

$776.47

0.04 (0.01%)

17:01
10/05/16
10/05
17:01
10/05/16
17:01

Twitter to end sales negotiations by time of Q3 earnings report, Reuters reports

Twitter (TWTR) has informed possible suitors that it is seeking to end negotiations about a buyout by the time it reports Q3 earnings on October 27, Reuters reports, citing people familiar with the matter. Binding offers are due in the next two weeks, and the company has already pared down its field of suitors, the report says. Salesforce (CRM) is in the mix, while Google parent Alphabet (GOOG) and Disney (DIS) have also considered making offers, the report says. Reference Link

TWTR

Twitter

$24.87

1.35 (5.74%)

GOOG

Alphabet

$776.47

0.04 (0.01%)

GOOGL

Alphabet Class A

$801.23

-1.56 (-0.19%)

DIS

Disney

$92.45

-0.14 (-0.15%)

CRM

Salesforce

$68.42

-4.21 (-5.80%)

  • 05

    Oct

  • 23

    Oct

  • 27

    Oct

  • 10

    Nov

  • 10

    Nov

  • 30

    Nov

  • 15

    Jan

TWTR Twitter
$24.87

1.35 (5.74%)

10/05/16
STFL
10/05/16
NO CHANGE
Target $93
STFL
Buy
Stifel still sees Salesforce acquisition of Twitter as 'highly unlikely'
Stifel analyst Tom Roderick notes that Salesforce (CRM) kicked off its annual Dreamforce User Conference yesterday amid reports that the company may be a potential suitor for Twitter (TWTR). The analyst still believes that a Salesforce acquisition of Twitter is "highly unlikely," both from a logistical standpoint and from a business model fit perspective. Regarding fundamentals, Roderick continues to view Salesforce as a leading driver of the enterprise shift to the Cloud, and sees no reason why that shouldn't continue to play out in the second half of 2017, in spite of recent concerns about the mid-year slowdown. He reiterates a Buy rating and $93 price target on Salesforce's shares.
10/05/16
BMOC
10/05/16
NO CHANGE
BMOC
Outperform
BMO says Salesforce's positive messages overshadowed by Twitter speculation
BMO Capital analyst Keith Bachman said the positive themes laid out by Salesforce (CRM) management at the company's Dreamforce event, such as guidance to reach $10B in FY18 revenues without inorganic sources of revenue, would traditionally help the stock. However, news reports, including the most recent from the Wall Street Journal, indicating that the company may buy Twitter (TWTR), will outweigh the "positive messages" of the event. If Salesforce were to buy Twitter, the stock would move meaningfully lower, Bachman predicted, but he also wonders if strategic buyers would then potentially consider buying Salesforce. The firm keeps its Outperform rating on Salesforce shares.
10/05/16
BOFA
10/05/16
NO CHANGE
Target $100
BOFA
Buy
Salesforce acquisition of Twitter 'quite low,' says BofA/Merrill
BofA/Merrill analyst Kash Rangan said the probability of Salesforce (CRM) acquiring Twitter (TWTR) is "quite low." The analyst does not believe Salesforce would materially dilute its shareholders with such a risky deal and expects the CEO to provide clarity on the thought process behind core software acquisitions versus media at today's Q&A session. Rangan rates Salesforce a Buy with a $100 price target on shares.
10/05/16
WEDB
10/05/16
NO CHANGE
WEDB
Outperform
Twitter worries obscuring positive trends for Salesforce, says Wedbush
Wedbush analyst Steve Koenig said his industry and partner checks don't point to any secular headwinds for Salesforce's (CRM) business, adding that the company gave several reassuring metrics on its progress in cross-selling, growing deal sizes, and expanding its large account base at its investor day event at the Dreamforce conference. At the investor day, management acknowledged conjecture about Salesforce trying to buy Twitter (TWTR), but deflected comments, with CFO Mark Hawkins suggesting that CEO Marc Benioff's Q&A session Wednesday afternoon may be a better forum for soliciting comments, noted Koenig. The analyst, who remains constructive on Salesforce as long as the company doesn't buy Twitter, keeps an Outperform rating on the shares.
GOOG Alphabet
$776.47

0.04 (0.01%)

09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
Wedbush analyst James Dix downgraded Alphabet to Underperform and lowered his price target on shares to $700 on concerns the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive.
09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
GOOGL Alphabet Class A
$801.23

-1.56 (-0.19%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
DIS Disney
$92.45

-0.14 (-0.15%)

09/26/16
UBSW
09/26/16
NO CHANGE
Target $92
UBSW
Neutral
Consumer satisfaction with competitors has caught up to Netflix, says UBS
UBS analyst Doug Mitchelson said that the firm's Evidence Lab survey indicated that U.S. consumer satisfaction with Amazon Prime Video (AMZN) and Hulu - the joint venture owned by Time Warner (TWX), Comcast (CMCSA), 21st Century Fox (FOXA), and Disney (DIS) - has now caught up to Netflix (NFLX), advising that investors should "continue to monitor competitive threats closely" as Netflix leads the category but demand for consumer media time, attention and wallet has intensified. The analyst, who added that Netflix's "pricing power remains unclear" based on the firm's survey work, keeps a Neutral rating and $92 price target on Netflix shares.
09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $16
SBSH
Neutral
Citi sees 40% downside in Twitter with no takeover bid
Citi analyst Mark May believes Twitter's (TWTR) risk/reward skews to the downside following the recent rally in the shares. A buyout of the company carries "strategic rationale for certain companies," but Twitter's "struggles and steep valuation" make a deal at a meaningful premium less likely, May tells investors in a research note. A takeover at $26 per share looks aggressive, May contends. He believes the stock could retest the lows of late May, representing 40% downside from current levels, should an acquisition offer not materialize. The analyst keeps a Neutral rating on Twitter with a $16 price target. The shares closed yesterday up 75c to $23.37 following reports that Disney (DIS) may be joining the list of potential acquires that already includes Alphabet (GOOG) and Salesforce (CRM).
09/26/16
09/26/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Drexel Hamilton with analyst Tony Wible saying he believes a large step up in NBA costs, incremental subscribers losses, difficult studio comps, a riskier studio slate, and Shanghai cost pressures will weigh on fiscal 2017. 2. Twitter (TWTR) downgraded to Underperform from Perform at Oppenheimer with analyst Jason Helfstein saying a media company is the most likely acquirer of Twitter and would not pay meaningfully more than the valuation implied by our price target. 3. RetailMeNot (SALE) downgraded to Sell from Hold at Stifel with analyst Scott Devitt saying third party data indicates that the company's traffic trends have deteriorated recently. 4. Finish Line (FINL) downgraded to Neutral from Buy at Buckingham with the firm's analyst believing shares will be range bound in medium term due to high comp expectations, cost savings will be offset by incentive compensation and other investments, and less compelling valuation. 5. NetApp (NTAP) downgraded to Sell from Hold at Deutsche Bank with analyst Sherri Scribner saying secular challenges in the storage market are not reflected in NetApp's current valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CRM Salesforce
$68.42

-4.21 (-5.80%)

10/05/16
JPMS
10/05/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan backs Overweight rating on Salesforce as Twitter speculation gears up
JPMorgan analyst Mark Murphy noted that speculation that Salesforce (CRM) could buy Twitter (TWTR) has ratcheted up into a higher gear, fueled by the latest report from the WSJ, and acknowledges the risk of a setback if the company goes forward with such a transformational M&A deal. However, he still views Salesforce as a "rare cloud asset" that can be a long-term share gainer and keeps an Overweight rating and $95 price target on the shares.

TODAY'S FREE FLY STORIES

AXS

AXIS Capital

$63.32

0.42 (0.67%)

08:31
12/09/16
12/09
08:31
12/09/16
08:31
Hot Stocks
AXIS Capital announces new $1B share repurchase authorization »

AXIS Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$43.22

0.51 (1.19%)

08:31
12/09/16
12/09
08:31
12/09/16
08:31
Hot Stocks
TD Ameritrade reports November client trades per day up 23% y/y »

TD Ameritrade announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRS

Aclaris Therapeutics

$28.97

-0.83 (-2.79%)

, NTLA

Intellia Therapeutics

$15.38

0.06 (0.39%)

08:30
12/09/16
12/09
08:30
12/09/16
08:30
Options
Two new option listings and three option delistings on December 9th »

New option listings for…

ACRS

Aclaris Therapeutics

$28.97

-0.83 (-2.79%)

NTLA

Intellia Therapeutics

$15.38

0.06 (0.39%)

LGF

Lionsgate

$26.09

1.1 (4.40%)

LNKD

LinkedIn

STRZA

Starz

$35.52

0.59 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$12.33

-0.3 (-2.38%)

08:30
12/09/16
12/09
08:30
12/09/16
08:30
Conference/Events
Pure Storage participates in a conference call with UBS »

UBS IT Hardware & EMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

08:30
12/09/16
12/09
08:30
12/09/16
08:30
General news
U.S. equities are back in the green »

U.S. equities are back in…

SGYP

Synergy Pharmaceuticals

$5.54

0.06 (1.09%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Hot Stocks
Breaking Hot Stocks news story on Synergy Pharmaceuticals »

Synergy Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

LFUS

Littelfuse

$154.58

3.1 (2.05%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Littelfuse to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WWD

Woodward

$70.84

-0.26 (-0.37%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Wayfair Woodward to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DVAX

Dynavax

$4.80

-0.2 (-4.00%)

08:25
12/09/16
12/09
08:25
12/09/16
08:25
Conference/Events
Dynavax to host research and development day »

Cancer Research and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 15

    Dec

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

08:24
12/09/16
12/09
08:24
12/09/16
08:24
Downgrade
Duluth Holdings rating change  »

Duluth Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBAI

Lakeland Bancorp

$19.15

0.3 (1.59%)

08:24
12/09/16
12/09
08:24
12/09/16
08:24
Syndicate
Breaking Syndicate news story on Lakeland Bancorp »

Lakeland Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSD

Clearside Biomedical

$11.53

-2.9 (-20.10%)

08:23
12/09/16
12/09
08:23
12/09/16
08:23
Syndicate
Clearside Biomedical 4M share Secondary priced at $9.00 »

JPMorgan, Cowen and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BIIB

Biogen

$289.54

4.24 (1.49%)

, LLY

Eli Lilly

$67.19

-0.19 (-0.28%)

08:21
12/09/16
12/09
08:21
12/09/16
08:21
Recommendations
Biogen, Eli Lilly analyst commentary  »

Biogen has positive read…

BIIB

Biogen

$289.54

4.24 (1.49%)

LLY

Eli Lilly

$67.19

-0.19 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

08:20
12/09/16
12/09
08:20
12/09/16
08:20
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

FNSR

Finisar

$34.13

1.89 (5.86%)

08:17
12/09/16
12/09
08:17
12/09/16
08:17
Recommendations
Finisar analyst commentary  »

Finisar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$83.39

0.47 (0.57%)

08:15
12/09/16
12/09
08:15
12/09/16
08:15
Recommendations
Zebra Technologies analyst commentary  »

Zebra Technologies prie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$170.71

2.16 (1.28%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Recommendations
Broadcom analyst commentary  »

Broadcom poised for above…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB Pharma

$30.84

-1.11 (-3.47%)

, MYL

Mylan

$36.06

1.56 (4.52%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Periodicals
UCB Pharma Vimpat patent 'thrown out' by patent office, Bronte Capital reports »

Argentum…

UCBJY

UCB Pharma

$30.84

-1.11 (-3.47%)

MYL

Mylan

$36.06

1.56 (4.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

HLT

Hilton

$26.24

-0.8 (-2.96%)

08:14
12/09/16
12/09
08:14
12/09/16
08:14
Downgrade
Hilton rating change  »

Hilton downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CDEV

Centennial Resource Development

$18.29

-0.32 (-1.72%)

08:12
12/09/16
12/09
08:12
12/09/16
08:12
Initiation
Centennial Resource Development initiated  »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTEA

Long Island Iced Tea

$4.91

0.2 (4.25%)

08:12
12/09/16
12/09
08:12
12/09/16
08:12
Hot Stocks
Long Island Iced Tea agrees to acquire ALO Juice »

Long Island Iced Tea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCON

Superconductor Technologies

$2.02

-0.13 (-6.05%)

08:11
12/09/16
12/09
08:11
12/09/16
08:11
Syndicate
Superconductor Technologies raises $10.2M in a public offering »

The offering was priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMG

Cellular Biomedicine

$13.35

0.1 (0.75%)

08:09
12/09/16
12/09
08:09
12/09/16
08:09
Hot Stocks
Cellular Biomedicine announces 3-month interim safety data from AlloJoin trial »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$89.30

5.57 (6.65%)

08:09
12/09/16
12/09
08:09
12/09/16
08:09
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIRG

Airgain

$18.62

-2.13 (-10.27%)

08:08
12/09/16
12/09
08:08
12/09/16
08:08
Syndicate
Airgain 2.35M share Secondary priced at $17.00 »

Cowen, William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.